SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors weigh the implications of a recent equity offering against the high-stakes anticipation surrounding imminent PsA Phase 3 trial data. The community is actively debating the likelihood of a strategic buyout by major pharmaceutical players, with sentiment largely driven by confidence in the potential best-in-class profile of their leading drug candidate.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors monitor its pipeline expansion and M&A strategy, particularly as the company seeks to address the upcoming patent cliff for Keytruda. The community is actively discussing potential buyout targets and partnerships, with various speculative links being drawn to companies like Sellas Life Sciences and Inhibrx.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is experiencing significant volatility as the market reacts to reports of a critical privacy-related bug, sparking intense debate within the community regarding its total supply and the reliability of its codebase. While some investors are panic selling over concerns about potential infinite supply exploits, others are aggressively buying the dip, viewing the emergency patch as a hardening of the network against future threats.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing investor attention as a high-quality compounder while navigating market volatility and regulatory discussions regarding credit card interest rates. Community discourse remains focused on the company's resilient transaction volume growth and its aggressive push into stablecoin and blockchain payment infrastructure.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block is surging following an earnings report that featured a dramatic 40% workforce reduction, with management highlighting AI integration as a catalyst for future operational efficiency and margin expansion. Community sentiment is sharply divided between investors optimistic about long-term cost-cutting and lean operations and those concerned that the massive layoffs signal deeper underlying competitive struggles against industry rivals.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML continues to be a focal point for investors as the critical bottleneck in the AI semiconductor supply chain, with community sentiment largely bullish due to the company's monopoly on EUV lithography and surging demand for advanced logic and memory chips. Discussions are heavily centered on upcoming earnings and the broader AI capex cycle, with traders actively debating the stock's valuation premium and monitoring key technical support levels to time their entries alongside broader sector volatility.

RoboStrategy is a venture capital investment firm that publicly trades a fund giving investors access to private & public companies leading in robotics and embodied AI.

RoboStrategy Inc

RoboStrategy, Inc.

RoboStrategy, Inc. is trending as investors rush to gain exposure to its unique portfolio of pre-IPO robotics and physical AI leaders like Figure AI. The community is actively debating the fund's long-term valuation potential versus its current volatility, with many comparing its rapid price action to other high-profile thematic fund launches.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos is generating significant buzz as traders analyze its technical base-building and staking yields, with ongoing community debate regarding the ecosystem's future viability and market performance. The discussion is further amplified by investors rotating into the ticker, coupled with activity surrounding new infrastructure developments and broader altcoin market movements.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Staking Mini ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Investors are closely monitoring the Grayscale Ethereum Mini Trust as market sentiment fluctuates amid broader volatility in the cryptocurrency sector. Community discussions are heavily centered on technical chart patterns, institutional inflows, and ongoing debates regarding Ethereum's utility versus Bitcoin's market dominance.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge Technologies ($SEDG) is currently drawing significant attention from the trading community, fueled by both speculative technical setups and the broader narrative of domestic solar policy protection. Traders are closely monitoring the stock's volume and options activity as it approaches key resistance levels, with community discourse divided between those betting on a major technical reversal and others cautioning against fundamental volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of "Hold" from Analysts

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) has been given a consensus rating of "Hold" by the eight ratings firms that are presently covering the company, Marketbeat...

MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (Mereo BioPharma or the Company) (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS...

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud...

MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100Kto Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ...

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 DEADLINE APPROACHING: Berger Montague...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines - MREO INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action...

Shareholders that lost money on Mereo BioPharma Group plc(MREO) should contact Levi & Korsinsky about pending Class Action - MREO

Shareholders that lost money on Mereo BioPharma Group plc(MREO) should contact Levi & Korsinsky about pending Class Action - MREO Shareholders that lost money on Mereo BioPharma Group plc(MREO...

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit MREO Deadline: MREO Investors with Losses in Excess of $100K...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Why Did RARE Stock Plunge Over 41% Today?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MREOMereo Biopharma

Fundamentals

Latest MREO News